ValuEngine Downgrades Seres Therapeutics, Inc. (MCRB) to Sell
Seres Therapeutics, Inc. (NASDAQ:MCRB) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Thursday.
Other analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Zacks Investment Research downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective (up previously from $15.00) on shares of Seres Therapeutics in a report on Friday, August 4th. Canaccord Genuity set a $20.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, August 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $17.00.
Shares of Seres Therapeutics (NASDAQ:MCRB) opened at 16.75 on Thursday. The company has a 50 day moving average of $14.64 and a 200 day moving average of $14.64. The company’s market cap is $678.58 million. Seres Therapeutics has a 1-year low of $8.86 and a 1-year high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.10). The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.00 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.70) EPS. Equities analysts expect that Seres Therapeutics will post ($2.48) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/22/valuengine-downgrades-seres-therapeutics-inc-mcrb-to-sell.html.
Several institutional investors have recently modified their holdings of MCRB. Voya Investment Management LLC bought a new stake in shares of Seres Therapeutics during the 2nd quarter worth approximately $114,000. American International Group Inc. lifted its holdings in shares of Seres Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 727 shares during the period. Advisor Group Inc. lifted its holdings in shares of Seres Therapeutics by 100.7% during the 2nd quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 7,050 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of Seres Therapeutics during the 2nd quarter worth approximately $169,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Seres Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 2,410 shares during the period. 74.76% of the stock is owned by institutional investors.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.